肿瘤相关性高凝的分子机制

doi:10.3760/cma.j.issn.1673-422X.2016.05.009

摘要/Abstract

摘要： 恶性肿瘤在其发生、局部浸润、远处转移的过程中会产生一系列分子改变，这些基因突变或表达异常的分子对机体中血液的高凝起到了促进作用，同时血液高凝也会增加肿瘤发展的几率，了解二者发生的具体过程及发生过程中各分子扮演的角色可为临床医师更好地管理相关患者提供理论依据，对于研发更有效、更安全的新型口服抗凝药物也具有重要意义。

关键词: 肿瘤, 血液凝固, 分子机制

Abstract: The process of tumorigenesis, local invasion and distant metastasis will produce a series of molecular changes, these genetic mutation or abnormal expression of molecules play a promoting role in hypercoagulation. At the same time, hypercoagulation also increases the risk of tumor progression. It is important to understand their specific processes and the molecular role, and it can provide theoretical basis for better management of patients, and has significance for developing more effective and security new anticlotting drugs.

Key words: Neoplasms, Blood coagulation, Molecular mechanism

张雪，姜达，李颖. 肿瘤相关性高凝的分子机制[J]. 国际肿瘤学杂志, 2016, 43(5): 356-359.

Zhang Xue, Jiang Da, Li Ying. Molecular mechanism of tumor associated hypercoagulability[J]. Journal of International Oncology, 2016, 43(5): 356-359.

参考文献

［1］赵晶, 姜达. 恶性肿瘤高凝状态及其干预［J］. 癌症进展, 2013, 11(1): 48-52. ［2］陈国荣. 恶性肿瘤患者血栓的形成机制与诊断进展［J］. 新乡医学院学报, 2015, 32(9): 891-893. ［3］ Anand M, Brat DJ. Oncogenic regulation of tissue factor and thrombosis in cancer［J］. Thromb Res, 2012, 129 Suppl 1: S46-S49. DOI: 10.1016/S00493848(12)700154. ［4］付晓飞, 杨之斌, 殷正丰. 血小板与循环肿瘤细胞［J］. 肿瘤, 2014, 34(3): 286-290. ［5］ Grane CA, Han SJ, Barry JJ, et al. TGFbeta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients［J］. Neuro Oncol, 2010, 12(1): 7-13. DOI: 10.1093/neuonc/nop009. ［6］ Gigante M, Gesualdo L, Ranieri E.TGFbeta: a master switch in tumor immunity［J］. Curr Pharm Des, 2012, 18(27): 4126-4134. ［7］ Van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside［J］. Blood, 2012, 119(4): 924-932. DOI: 10.1182/blood201106317685. ［8］ Godby RC, van den Berg YW, Srinvasan RS, et al. Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrinmediated signaling in murine models［J］. Mol Med, 2012, 18(1): 771-779. DOI: 10.2119/molmed.2011.00416. ［9］ Srinivasan R, Ozhegov E, van den Berg YW, et al. Splice variants of tissue factor promote monocyteendothelial interactions by triggering the expression of cell adhesion molecules via integrinmediated signaling［J］. Thromb Haemost, 2011, 9(10): 2087-2096. DOI: 10.1111/j.15387836.2011.04454. ［10］ Ettelaie C, Collier ME, Mei MP, et al. Enhanced binding of tissue factor microparticles to collagenⅣ and fibronectin leads to increased tissue factor activity in vitro［J］. Thromb Haemost, 2013, 109(1): 61-71. DOI: 10.1160/TH12050279. ［11］ Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations［J］. Proc Natl Acad Sci USA, 2014, 111(9): 3544-3549. ［12］ Breij EC, de Goeij BE, Verploegen S, et al. An antibodydrug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors［J］. Caner Res, 2014, 74(4): 1214-1226. DOI: 10.1158/00085472.CAN132440. ［13］ Garnier D, Magnus N, Lee TH, et al. Cancer cells induced to express mesenchymal phenotype release exosomelike extracellular vesicles carrying tissue factor［J］. J Biol Chem， 2012, 287(52): 43565-43572. DOI: 10.1074/jbc.M112. 401760. ［14］ Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissuefactorbearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation［J］. Blood, 2005, 106(5): 1604-1611. ［15］ Hathcock J, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Ⅹa［J］. Blood, 2004, 104(1):123-127. ［16］ Zwicker JI, Liebman H, Neuberg D, et al. Tumorderived tissue factorbearing microparticles are associated with venous thromboembolic events in malignancy［J］. Clin Cancer Res, 2009, 15(22): 6830-6840. DOI: 10.1158/10780432. CCR090371. ［17］ Nadir Y, Brenner B. Heparanase multiple effects in cancer［J］. Thromb Res, 2014, 133Suppl 2: S90-S94. DOI: 10.1016/S00493848(14)500151. ［18］ Menschikowski M, Hagelgans A, Tiebel O, et al. Regulation of thrombomodulin expression in prostate cancer cells［J］. Cancer Lett, 2012, 322(2): 177-184. DOI: 10.1016/j.canlet.2012.03.001. ［19］ Chen LM, Wang W, Lee JC, et al. Thrombomodulin mediates the progression of epithelial ovarian cancer cells［J］. Tumour Biol, 2013, 34(6): 3743-3751. DOI: 10.1007/s132770130958x. ［20］ Demers M, Wagner DD. Neutrophil extracellular traps: A new link to cancerassociated thrombosis and potential implications for tumor progression［J］. Oncol Immunol, 2013, 2(2): e22946. ［21］ Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancerassociated thrombosis［J］. Proc Natl Acad Sci USA, 2012, 109(32): 13076-13081. DOI: 10.1073/pnas.1200419109. ［22］ Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases［J］. Nat Med， 2010, 16(8): 887-896. DOI: 10.1038/nm.2184. ［23］ Buck K, Hug S, Seibold P, et al. CD24 polymorphisms in breast cancer: impact on prognosis and risk［J］. Breast Cancer Res Treat, 2013, 137(3): 927-937. DOI: 10.1007/s1054901223259. ［24］ Bretz NP, Salnikov AV, Perne C, et al. CD24 controls Src/STAT3 activity in human tumors［J］. Cell Mol Life Sci, 2012, 69(22): 3863-3879. DOI: 10.1007/s0001801210559. ［25］ Kang KS, Choi YP, Gao MQ, et al. CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype［J］. Biochem Biophys Res Commun, 2013, 432(2): 333-338. DOI: 10.1016/j.bbrc.2013.01.102. ［26］ Rao B, Gao Y, Huang J, et al. Mutations of p53 and Kras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis［J］. Int J Colorectal Dis, 2011, 26(5): 593-601. DOI: 10.1007/s00384 01111641. ［27］ Yu JL, Xing R, Milsom C, et al. Modulation of the oncogenedependent tissue factor expression by kinase suppressor of ras1［J］. Thromb Res, 2010, 126(1): e6-e10. DOI: 10.1016/j.thromres.2010.04.014.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.